Parathyroid Hormone

The majority of adults with hypoparathyroidism achieved normal serum calcium levels with palopegteriparatide at 1 year without supplemental vitamin D or calcium, according to data from a phase 3 open-label extension.

A parathyroid hormone prodrug developed to treat hypoparathyroidism received FDA approval, according to an industry press release.

Approximately 77,000 people in the U.S. have hypoparathyroidism due to absent or subphysiological levels of parathyroid hormone.

A once-weekly oral vitamin D supplementation did not reduce fracture risk over a 3-year follow-up among a group of children with vitamin D deficiency in Mongolia, according to findings published in The Lancet Diabetes & Endocrinology.

Using lower parathyroid hormone targets to manage secondary hyperparathyroidism may lower mortality and CVD in patients on hemodialysis, a study found.

The FDA has rejected a new drug application for an agent to treat adults with hypoparathyroidism due to concerns with manufacturing control strategy, according to an industry press release.

The FDA granted orphan drug designation to an investigational therapy to treat hypoparathyroidism, according to an industry press release.

Chronic hypoparathyroidism can be a debilitating disease for those living with the condition, with patients reporting daily symptoms such as physical fatigue, muscle cramps, and limb heaviness and tingling.

There is minimal difference among bioavailable, free and total serum 25-hydroxyvitamin D for predicting bone health in older adults, according to data presented at the American Society for Bone and Mineral Research virtual meeting.

For patients with kidney disease, calcimimetic agents lowered parathyroid hormone levels in the short term, with each agent consisting of a different side-effect profile, according to a systematic study review.